The quest for a fixed-dose immunosuppressive drug has not yet materialized. We have learned over the years that the dose and or blood levels correlate poorly with the clinical events. It was also clear that there are intra and inter-patient pharmacokinetic variabilities blood trough levels and area under the curve (AUC) for all maintenance therapy. It is also important to recognize that in many centers multi organs are being transplanted in adults, pediatrics and the immunocompromised recipient which necessitate different immunosuppressive protocols. This led many centers to establish their own immunosuppressive protocols from induction therapy, maintenance therapy as well as allograft rejection therapy. In this class, the two speakers will address these issues.
Presentation: Immunosuppressive therapy in the sensitized patients, Jeremy Chapman, Australia
Live Q&A with Jeremy Chapman, Australia
Presentation: Personalized immunosuppression: is it justified?, Hassan Argani, Iran
Live Q&A with Hassan Argani, Iran
Masterclass closing remarks